Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 28-Feb-23 4:29 PM View:  | 5am Partners Vi, LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 4,937,650 | -- | -- | (100%) 4.94M to 0 | |
| 24-Feb-23 6:36 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 1,500 | -- | -- | (100%) 1.5K to 0 | |
| 24-Feb-23 6:34 PM View: | de Garidel Marc Chief Executive Officer Director | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 12,500 | -- | -- | (100%) 12.5K to 0 | |
| 27-Feb-23 5:10 PM View: | Freeman Mason Chief Medical Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition | 40,000 | -- | -- | (94%) 42.59K to 2.59K | |
| 27-Feb-23 9:15 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 9,803 | -- | -- | (< 1%) 6.08M to 6.07M | |
| 24-Feb-23 6:38 PM View: | Kalb Michael Wayne EVP & Chief Financial Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition | 202,437 | -- | -- | (100%) 202.44K to 0 | |
| 27-Feb-23 5:10 PM View: | Freeman Mason Chief Medical Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 2,494 | -- | -- | (96%) 2.59K to 100 | |
| 27-Feb-23 9:15 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 6,073,950 | -- | -- | (100%) 6.07M to 0 | |
| 24-Feb-23 6:36 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition | 15,000 | -- | -- | (10%) 156.65K to 141.65K | |
| 24-Feb-23 6:36 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 140,149 | -- | -- | (99%) 141.65K to 1.5K | |
| 24-Feb-23 6:34 PM View: | de Garidel Marc Chief Executive Officer Director | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition | 200,000 | -- | -- | (94%) 212.5K to 12.5K | |
| 27-Feb-23 5:10 PM View: | Freeman Mason Chief Medical Officer | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition (change in control) | 100 | -- | -- | (100%) 100 to 0 | |
| 27-Feb-23 9:15 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 24-Feb-23 | Disposition | 19,608 | -- | -- | (< 1%) 6.1M to 6.08M | |
| 30-Jan-23 8:04 PM View: | Kalb Michael Wayne EVP & Chief Financial Officer | Cincor Pharma, Inc. (CINC) | 26-Jan-23 | Grant | 177,000 | -- | -- | 696% 25.44K to 202.44K | |
| 30-Jan-23 8:07 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 26-Jan-23 | Grant | 15,000 | -- | -- | 11% 141.65K to 156.65K | |
| 30-Jan-23 8:08 PM View: | de Garidel Marc Chief Executive Officer Director | Cincor Pharma, Inc. (CINC) | 26-Jan-23 | Grant | 200,000 | -- | -- | 1600% 12.5K to 212.5K | |
| 30-Jan-23 8:03 PM View: | Freeman Mason Chief Medical Officer | Cincor Pharma, Inc. (CINC) | 26-Jan-23 | Grant | 40,000 | -- | -- | 1538% 2.6K to 42.6K | |
| 19-Jan-23 4:34 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 11-Jan-23 | Payment of Exercise | 3,997 | $28.75 | $114,914.00 | (3%) 145.65K to 141.65K | |
| 19-Jan-23 4:34 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 11-Jan-23 | Option Exercise | 13,235 | -- | -- | 10% 132.41K to 145.65K | |
| 27-Feb-23 9:15 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 28-Nov-22 | Market Sale | 6,000 | $14.32 | $85,920.00 | (< 1%) 6.11M to 6.1M | 1% |
| 08-Nov-22 5:08 PM View: | Kalb Michael Wayne EVP & Chief Financial Officer | Cincor Pharma, Inc. (CINC) | 04-Nov-22 | Grant | 25,437 | -- | -- | 100% 0 to 25.44K | |
| 17-Aug-22 4:19 PM View: | Sofinnova Partners Sas 10% Owner | Cincor Pharma, Inc. (CINC) | 15-Aug-22 | Purchase | 133,333 | $30.00 | $3,999,990.00 | 3% 4.09M to 4.22M | |
| 17-Aug-22 8:01 PM View: | 5am Partners Vi, LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 15-Aug-22 | Purchase | 600,000 | $30.00 | $18,000,000.00 | 14% 4.34M to 4.94M | |
| 15-Aug-22 2:21 PM View: | General Atlantic Partners LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Aug-22 | Purchase | 83,000 | $30.00 | $2,490,000.00 | 2% 4.13M to 4.21M | |
| 15-Aug-22 2:22 PM View: | General Atlantic Genpar (be... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Aug-22 | Purchase Duplicate | 83,000 | $30.00 | $2,490,000.00 | 2% 4.13M to 4.21M | |
| 15-Aug-22 3:45 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Aug-22 | Purchase | 506,000 | $30.00 | $15,180,000.00 | 9% 5.6M to 6.11M | |
| 15-Aug-22 3:46 PM View: | Sofinnova Venture Partners ... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Aug-22 | Purchase | 500,000 | $30.00 | $15,000,000.00 | 9% 5.57M to 6.07M | |
| 08-Aug-22 12:57 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 05-Aug-22 | Option Exercise | 29,411 | $13.60 | $399,990.00 | < 1% 5.57M to 5.6M | 4% |
| 27-Feb-23 5:10 PM View: | Freeman Mason Chief Medical Officer | Cincor Pharma, Inc. (CINC) | 10-Jun-22 | Market Sale | 6 | $15.21 | $91.26 | (< 1%) 2.6K to 2.59K | 7% |
| 13-Jan-22 4:36 PM View: | Sofinnova Partners Sas 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion | 3,867,650 | -- | -- | 100% 0 to 3.87M | |
| 13-Jan-22 4:38 PM View: | Sofinnova Venture Partners ... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion Duplicate | 5,248,950 | -- | -- | 100% 0 to 5.25M | |
| 13-Jan-22 4:45 PM View: | 5am Partners Vi, LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion Duplicate | 3,867,650 | -- | -- | 100% 0 to 3.87M | |
| 13-Jan-22 4:31 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase | 1,500 | $16.00 | $24,000.00 | 1% 130.91K to 132.41K | (12%) |
| 13-Jan-22 4:26 PM View: | de Garidel Marc Chief Executive Officer Director | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase | 12,500 | $16.00 | $200,000.00 | 100% 0 to 12.5K | (12%) |
| 13-Jan-22 4:33 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion | 5,248,950 | -- | -- | 100% 0 to 5.25M | |
| 13-Jan-22 4:36 PM View: | Sofinnova Partners Sas 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase | 220,000 | $16.00 | $3,520,000.00 | 6% 3.87M to 4.09M | |
| 13-Jan-22 4:38 PM View: | Sofinnova Venture Partners ... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase Duplicate | 325,000 | $16.00 | $5,200,000.00 | 6% 5.25M to 5.57M | |
| 13-Jan-22 4:45 PM View: | 5am Partners Vi, LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase | 470,000 | $16.00 | $7,520,000.00 | 12% 3.87M to 4.34M | |
| 13-Jan-22 9:32 PM View: | General Atlantic Partners LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion | 2,426,470 | -- | -- | 100% 2.43M to 4.85M | |
| 13-Jan-22 9:32 PM View: | General Atlantic Genpar (be... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion Duplicate | 2,426,470 | -- | -- | 100% 2.43M to 4.85M | |
| 13-Jan-22 4:40 PM View: | Cinrx Pharma, LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Conversion | 1,222,530 | -- | -- | 51% 2.41M to 3.63M | |
| 13-Jan-22 4:28 PM View: | Freeman Mason EVP Clinical Development | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase | 2,500 | $16.00 | $40,000.00 | 100% 0 to 2.5K | (12%) |
| 13-Jan-22 4:33 PM View: | Healy James Director 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase | 325,000 | $16.00 | $5,200,000.00 | 6% 5.25M to 5.57M | |
| 13-Jan-22 4:31 PM View: | Pearce Catherine Chief Operating Officer | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase | 750 | $16.00 | $12,000.00 | < 1% 130.16K to 130.91K | (12%) |
| 13-Jan-22 9:32 PM View: | General Atlantic Partners LLC 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase | 1,700,000 | $16.00 | $27,200,000.00 | 35% 4.85M to 6.55M | |
| 13-Jan-22 9:32 PM View: | General Atlantic Genpar (be... 10% Owner | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Purchase Duplicate | 1,700,000 | $16.00 | $27,200,000.00 | 35% 4.85M to 6.55M | |
| 13-Jan-22 4:24 PM View: | Coelho Mary Theresa EVP CFO & Chief BD Officer | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase | 100 | $16.00 | $1,600.00 | 100% 0 to 100 | (12%) |
| 13-Jan-22 4:28 PM View: | Freeman Mason EVP Clinical Development | Cincor Pharma, Inc. (CINC) | 11-Jan-22 | Market Purchase Duplicate | 100 | $16.00 | $1,600.00 | 4% 2.5K to 2.6K | (12%) |
